Sarepta Therapeutics (SRPT) Short Interest Ratio & Short Volume $39.99 +2.05 (+5.40%) As of 05/20/2025 04:00 PM Eastern Add Compare Share Share Short Interest Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock Sarepta Therapeutics Short Interest DataSarepta Therapeutics (SRPT) has a short interest of 6.70 million shares. This marks a 1.21% increase in short interest from the previous month. The short interest ratio (days to cover) is 2.5, indicating that it would take 2.5 days of the average trading volume of 1.74 million shares to cover all short positions.Current Short Interest6,700,000 sharesPrevious Short Interest6,620,000 sharesChange Vs. Previous Month+1.21%Dollar Volume Sold Short$418.08 millionShort Interest Ratio2.5 Days to CoverLast Record DateApril 30, 2025Outstanding Shares98,277,000 sharesPercentage of Shares Shorted6.82%Today's Trading Volume4,909,209 sharesAverage Trading Volume1,736,702 sharesToday's Volume Vs. Average283% Short Selling Sarepta Therapeutics? Sign up to receive the latest short interest report for Sarepta Therapeutics and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort Interest ChartDays to Cover ChartShort Percent of Float ChartSRPT Short Interest Over TimeSRPT Days to Cover Over TimeSRPT Percentage of Float Shorted Over Time Sarepta Therapeutics Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 4/30/20256,700,000 shares $418.08 million +1.2%N/A2.5 $62.40 4/15/20256,620,000 shares $360.26 million +8.5%7.5%3.5 $54.42 3/31/20256,100,000 shares $389.30 million +25.8%6.9%3.7 $63.82 3/15/20254,850,000 shares $471.37 million -4.2%5.5%3.9 $97.19 2/28/20255,060,000 shares $540.16 million +2.9%5.7%6 $106.75 2/15/20254,920,000 shares $531.11 million -2.6%5.6%5.6 $107.95 1/31/20255,050,000 shares $574.29 million +1.4%N/A5.3 $113.72 1/15/20254,980,000 shares $594.26 million -2.9%N/A5.3 $119.33 12/31/20245,130,000 shares $623.76 million -8.2%N/A5.5 $121.59 12/15/20245,590,000 shares $691.54 million -4.0%N/A5.8 $123.71 Get the Latest News and Ratings for SRPT and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Sarepta Therapeutics and its competitors with MarketBeat's FREE daily newsletter. 11/30/20245,820,000 shares $776.04 million +15.5%N/A6 $133.34 11/15/20245,040,000 shares $526.88 million -10.0%N/A5.5 $104.54 10/31/20245,600,000 shares $705.60 million -1.1%N/A6.6 $126.00 10/15/20245,660,000 shares $700.31 million -8.6%N/A6 $123.73 9/30/20246,190,000 shares $773.07 million +0.7%N/A6.1 $124.89 9/15/20246,150,000 shares $766.60 million -5.8%N/A5.3 $124.65 8/31/20246,530,000 shares $886.64 million -3.0%N/A4.4 $135.78 8/15/20246,730,000 shares $897.38 million +0.2%N/A3.5 $133.34 7/31/20246,720,000 shares $955.85 million -8.3%N/A3.5 $142.24 7/15/20247,330,000 shares $1.12 billion -23.3%N/A3.9 $152.67 6/30/20249,560,000 shares $1.51 billion +1.1%N/A5.4 $158.00 6/15/20249,460,000 shares $1.16 billion +45.8%N/A5.7 $122.84 5/31/20246,490,000 shares $842.79 million -1.1%N/A5.1 $129.86 5/15/20246,560,000 shares $869.20 million +15.3%N/A7.3 $132.50 4/30/20245,690,000 shares $720.70 million +16.8%N/A6.2 $126.66 4/15/20244,870,000 shares $576.17 million +5.9%N/A5.8 $118.31 3/31/20244,600,000 shares $595.52 million -7.4%N/A4.5 $129.46 3/15/20244,970,000 shares $611.56 million +4.0%N/A4.6 $123.05 2/29/20244,780,000 shares $611.36 million -0.6%N/A4 $127.90 2/15/20244,810,000 shares $600.72 million -7.0%N/A4.1 $124.89 1/31/20245,170,000 shares $615.18 million -9.0%N/A4.1 $118.99 1/15/20245,680,000 shares $663.42 million +21.1%N/A3.2 $116.80 12/31/20234,690,000 shares $452.26 million -0.4%N/A2.7 $96.43 12/15/20234,710,000 shares $437.98 million +10.6%N/A2.9 $92.99 11/30/20234,260,000 shares $346.25 million +0.2%N/A2.8 $81.28 11/15/20234,250,000 shares $355.98 million -4.5%N/A2.9 $83.76 10/31/20234,450,000 shares $299.53 million -8.8%N/A3 $67.31 10/15/20234,880,000 shares $575.64 million +1.2%N/A5.4 $117.96 9/30/20234,820,000 shares $584.28 million +6.6%N/A5.2 $121.22 9/15/20234,520,000 shares $535.17 million -2.0%N/A4.6 $118.40Elon just did WHAT!? (Ad)As you may recall, Biden and the Fed were working on a central bank digital currency, or CBDC. Had they gotten away with it, the Fed and U.S. banks could have seized control of our financial lives forever. But Trump stopped them cold on January 23rd, 2025, when he outlawed CBDCs… Paving the way for Elon Musk's secret master plan.Click here to see how to claim your stake before they launch to avoid missing out. 8/31/20234,610,000 shares $557.86 million +4.1%N/A4.3 $121.01 8/15/20234,430,000 shares $505.37 million -0.5%N/A3.8 $114.08 7/31/20234,450,000 shares $482.34 million -9.9%N/A3.2 $108.39 7/15/20234,940,000 shares $532.70 million -1.0%N/A3.5 $107.84 6/30/20234,990,000 shares $571.45 million +9.7%N/A3.3 $114.52 6/15/20234,550,000 shares $598.83 million +2.9%N/A3.1 $131.61 5/31/20234,420,000 shares $546.31 million +17.9%N/A2.8 $123.60 5/15/20233,750,000 shares $589.46 million -8.5%N/A2.2 $157.19 4/30/20234,100,000 shares $503.36 million -8.5%N/A2.8 $122.77 4/15/20234,480,000 shares $549.38 million -5.1%N/A3.1 $122.63 3/31/20234,720,000 shares $650.56 million -13.2%N/A3.4 $137.83 3/15/20235,440,000 shares $791.36 million -32.7%N/A4 $145.47 2/28/20238,080,000 shares $986.81 million +7.0%N/A7.1 $122.13 2/15/20237,550,000 shares $941.64 million +12.4%N/A8.1 $124.72 1/31/20236,720,000 shares $839.80 million +8.9%N/A7.3 $124.97 1/15/20236,170,000 shares $781.74 million -9.8%N/A6.5 $126.70 12/30/20226,840,000 shares $886.33 million -1.0%N/A7.3 $129.58 12/15/20226,910,000 shares $861.33 million -1.0%N/A7.5 $124.65 11/30/20226,980,000 shares $857.21 million -5.0%N/A6.5 $122.81 11/15/20227,350,000 shares $806.15 million -8.6%N/A7.2 $109.68 10/31/20228,040,000 shares $916.72 million +11.1%N/A7.5 $114.02 10/15/20227,240,000 shares $814.14 million -1.4%N/A6.4 $112.45 9/30/20227,340,000 shares $811.36 million +7.6%N/A6.7 $110.54 9/15/20226,820,000 shares $754.84 million +4.1%N/A6 $110.68 8/31/20226,550,000 shares $716.44 million -4.5%N/A6.7 $109.38 8/15/20226,860,000 shares $748.01 million +34.3%N/A7.2 $109.04 7/31/20225,110,000 shares $474.97 million -4.7%N/A5.5 $92.95 7/15/20225,360,000 shares $448.04 million +2.7%N/A6.8 $83.59 6/30/20225,220,000 shares $391.29 million +4.8%N/A6.7 $74.96 6/15/20224,980,000 shares $321.21 million -0.4%N/A6.7 $64.50 5/31/20225,000,000 shares $364.10 million -2.0%N/A7 $72.82 5/15/20225,100,000 shares $336.45 million +5.6%N/A6.7 $65.97 4/30/20224,830,000 shares $349.31 million -1.2%N/A6.6 $72.32 4/15/20224,890,000 shares $398.29 million -5.4%N/A6.2 $81.45 3/31/20225,170,000 shares $403.88 million -2.5%N/A5.2 $78.12 3/15/20225,300,000 shares $403.70 million -1.1%N/A5.4 $76.17 2/28/20225,360,000 shares $410.63 million -2.2%N/A5.4 $76.61 2/15/20225,480,000 shares $445.80 million -6.8%N/A5.6 $81.35 1/31/20225,880,000 shares $420.83 million +30.1%N/A5.8 $71.57 1/15/20224,520,000 shares $321.37 million -1.3%N/A4.3 $71.10 12/31/20214,580,000 shares $412.43 million -15.0%N/A4.4 $90.05 12/15/20215,390,000 shares $470.71 million -1.1%N/A5.2 $87.33 11/30/20215,450,000 shares $440.41 million +16.5%N/A5.2 $80.81 11/15/20214,680,000 shares $392.56 million +2.0%N/A4.7 $83.88 10/29/20214,590,000 shares $363.21 million -8.8%N/A4.7 $79.13 10/15/20215,030,000 shares $423.48 million -0.2%N/A5.3 $84.19 9/30/20215,040,000 shares $466.10 million -11.0%6.7%6 $92.48 9/15/20215,660,000 shares $475.72 million -3.6%7.5%7.3 $84.05 8/31/20215,870,000 shares $458.56 million -5.0%7.8%7.5 $78.12 8/13/20216,180,000 shares $494.03 million -2.4%8.2%6.7 $79.94URGENT: Someone's Moving Gold Out of London... (Ad)People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “gold analysts” have it all wrong… They tell you to invest in gold ETFs - because the popular mining ETFs will someday catch fire and close the price gap with spot gold. Go here to learn about my Top Four picks for the coming bull mania. 7/30/20216,330,000 shares $429.05 million -2.5%8.3%6 $67.78 7/15/20216,490,000 shares $443.72 million +0.8%8.5%5.9 $68.37 6/30/20216,440,000 shares $500.65 million -3.3%8.5%5.9 $77.74 6/15/20216,660,000 shares $553.71 million -16.7%8.8%5.8 $83.14 5/28/20217,990,000 shares $604.44 million +4.0%10.5%6.9 $75.65 5/14/20217,680,000 shares $556.88 million +8.0%N/A6.6 $72.51 4/30/20217,110,000 shares $507.73 million -2.2%N/A6.3 $71.41 4/15/20217,270,000 shares $533.84 million -0.7%N/A6.3 $73.43 3/31/20217,320,000 shares $535.09 million +7.3%N/A3.5 $73.10 3/15/20216,820,000 shares $589.73 million -6.8%N/A3.3 $86.47 2/26/20217,320,000 shares $624.03 million +8.9%N/A3.6 $85.25 2/12/20216,720,000 shares $609.97 million -13.3%N/A3.6 $90.77 1/29/20217,750,000 shares $698.51 million -4.3%N/A4.1 $90.13 1/15/20218,100,000 shares $728.19 million +14.6%N/A4.6 $89.90 12/31/20207,070,000 shares $1.21 billion -10.6%N/A5 $171.54 12/15/20207,910,000 shares $1.34 billion -9.1%N/A11.3 $169.54 11/30/20208,700,000 shares $1.21 billion +5.2%N/A12.7 $139.15 11/15/20208,270,000 shares $1.17 billion -6.2%N/A11.6 $141.40 10/30/20208,820,000 shares $1.25 billion -0.6%N/A12.1 $141.49 10/15/20208,870,000 shares $1.29 billion -2.9%N/A13.5 $145.12 9/30/20209,130,000 shares $1.28 billion +0.7%N/A13.1 $140.43 9/15/20209,070,000 shares $1.30 billion -4.1%N/A12.5 $142.80 8/31/20209,460,000 shares $1.39 billion -3.2%N/A12 $146.42 8/14/20209,770,000 shares $1.53 billion -3.0%N/A11.7 $157.00 7/31/202010,070,000 shares $1.55 billion -3.5%N/A11.4 $153.52 7/15/202010,440,000 shares $1.74 billion -2.1%14.1%11.6 $166.76 6/30/202010,660,000 shares $1.73 billion -9.9%14.4%11.7 $162.71 6/15/202011,830,000 shares $1.88 billion +1.4%16.0%12.4 $158.85 5/29/202011,670,000 shares $1.78 billion +1.0%15.8%12 $152.27 SRPT Short Interest - Frequently Asked Questions What is Sarepta Therapeutics' current short interest? Short interest is the volume of Sarepta Therapeutics shares that have been sold short but have not yet been covered or closed out. As of April 30th, investors have sold 6,700,000 shares of SRPT short. Learn More on Sarepta Therapeutics' current short interest. What is a good short interest ratio for Sarepta Therapeutics? The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. SRPT shares currently have a short interest ratio of 2.0. Learn More on Sarepta Therapeutics's short interest ratio. Which institutional investors are shorting Sarepta Therapeutics? As of the most recent reporting period, the following institutional investors, funds, and major shareholders have reported short positions of Sarepta Therapeutics: Jane Street Group LLC, Goldman Sachs Group Inc., Parallax Volatility Advisers L.P., Royal Bank of Canada, Nomura Holdings Inc., Twin Tree Management LP, PEAK6 LLC, Jane Street Group LLC, Walleye Trading LLC, Walleye Capital LLC, Garda Capital Partners LP, JPMorgan Chase & Co., Wolverine Asset Management LLC, Citigroup Inc., Sivik Global Healthcare LLC, and IMC Chicago LLC. These positions are disclosed in Form 13F filings with the Securities and Exchange Commission. Is Sarepta Therapeutics' short interest increasing or decreasing? Sarepta Therapeutics saw a increase in short interest during the month of April. As of April 30th, there was short interest totaling 6,700,000 shares, an increase of 1.2% from the previous total of 6,620,000 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. How does Sarepta Therapeutics' short interest compare to its competitors? Here is how the short interest of companies in the industry of "pharmaceutical products" compare to Sarepta Therapeutics: Intra-Cellular Therapies, Inc. (2.58%), Genmab A/S (0.39%), Dr. Reddy's Laboratories Limited (1.79%), Viatris Inc. (4.27%), Moderna, Inc. (17.58%), Qiagen (2.35%), Ascendis Pharma A/S (6.40%), Roivant Sciences Ltd. (12.03%), Revolution Medicines, Inc. (8.89%), BridgeBio Pharma, Inc. (11.68%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: Spotify Technology S.A. ($4.67 billion), Charter Communications, Inc. ($4.58 billion), Capital One Financial Co. ($4.47 billion), The Kroger Co. ($2.56 billion), Reddit, Inc. ($2.23 billion), Rivian Automotive, Inc. ($2.16 billion), Live Nation Entertainment, Inc. ($1.90 billion), SoFi Technologies, Inc. ($1.85 billion), Zscaler, Inc. ($1.75 billion), and Omnicom Group Inc. ($1.75 billion). View all of the most shorted stocks. What does it mean to sell short Sarepta Therapeutics stock? Short selling SRPT is an investing strategy that aims to generate trading profit from Sarepta Therapeutics as its price is falling. SRPT shares are trading up $2.05 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against Sarepta Therapeutics? A short squeeze for Sarepta Therapeutics occurs when it has a large amount of short interest and its stock increases in price. This forces short sellers to cover their short interest positions by buying actual shares of SRPT, which in turn drives the price of the stock up even further. How often is Sarepta Therapeutics' short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including SRPT, twice per month. The most recent reporting period available is April, 30 2025. More Short Interest Resources from MarketBeat Related Companies ITCI Short Interest GMAB Short Interest RDY Short Interest VTRS Short Interest MRNA Short Interest QGEN Short Interest ASND Short Interest ROIV Short Interest RVMD Short Interest BBIO Short Interest Short Interest Tools Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NASDAQ:SRPT) was last updated on 5/21/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredBuffett’s favorite chart just hit 209% – here’s what that means for goldA Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the ...Golden Portfolio | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredIs President Trump Lying To You With This?President Trump’s economic transition isn’t without hardship. But what if there were a smart, tax-free way to ...Colonial Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Sarepta Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Sarepta Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy SRPT Stock Free SRPT Stock Alerts